Prospective, Open-Label, Single-Center, Non-Comparative Study to Assess the Use of Pixel CO2 Laser System (FemiLift) in the Treatment of Vulvovaginal Atrophy (VVA) in Postmenopausal Female Subjects

Inclusion Criteria: * Healthy, non-smoking * Woman, age 35 to 70 yrs, menopausal * Provided written Informed Consent * Exhibiting VVA and/or SUI symptoms (mild or moderate SUI, according to severity index developed by Sandvik.) * Prolapse staged \< II, according to the pelvic organ prolapse quantification (ICS-POP-Q) system * Normal PAP smear (up to 1 year prior to baseline) * Vaginal canal, introitus and vestibule free of injuries and bleeding * Have not had procedures in the anatomical area through 6 months prior to treatment * Understand and accept the obligation and is logistically able to present for all scheduled follow-up visits Exclusion Criteria: * Severe prolapse (POP\>= grade 3) * Use of photosensitive drugs * Acute or recurrent urinary tract infection (UTI), or genital infection (e.g. herpes candida). * Any serious disease, or chronic condition, that could interfere with the study compliance * Acute or actively present within the last 2 months HPV/HSV * Undiagnosed vaginal bleeding * Urge or overflow incontinence * Patients who are on antidepressants, or α-adrenergic and anticholinergic medications * Patients with immune system diseases. * Patients with allergic reaction to laser. * Obese women (BMI \>30) * Patient unable to follow post-treatment instructions * History of keloid formation * Received or is anticipated to receive antiplatelets, anticoagulants, thrombolytics, vitamin E or anti inflammatories within 2 weeks pre treatment * A history of thrombophleb…